Form 8-K - Current report:
SEC Accession No. 0000950170-23-002137
Filing Date
2023-02-08
Accepted
2023-02-08 16:09:11
Documents
13
Period of Report
2023-02-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K me-20230208.htm   iXBRL 8-K 62738
2 EX-99.1 me-ex99_1.htm EX-99.1 815654
  Complete submission text file 0000950170-23-002137.txt   1034717

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT me-20230208.xsd EX-101.SCH 2465
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT me-20230208_pre.xml EX-101.PRE 11111
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT me-20230208_lab.xml EX-101.LAB 17928
7 EXTRACTED XBRL INSTANCE DOCUMENT me-20230208_htm.xml XML 4544
Mailing Address 349 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 349 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 (650) 938-6300
23andMe Holding Co. (Filer) CIK: 0001804591 (see all company filings)

EIN.: 871240344 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-39587 | Film No.: 23599181
SIC: 2834 Pharmaceutical Preparations